KAT6A and neoplasm: TGFβ is also produced by MDSCs for inhibiting the antitumor immunity, resulting in upregulated tumor burden.[60] Thus, the KAT6A/SMAD3 signaling and tumor‐derived MDSCs may form a positive feedback regulatory network, resulting in aggressive TNBC properties.